BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Woltering EA, Hilton RS, Zolfoghary CM, Thomson J, Zietz S, Go VL, Vinik AI, Vinik E, O'Dorisio TM, Mamikunian G. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency. Pancreas 2006;33:250-4. [PMID: 17003646 DOI: 10.1097/01.mpa.0000235302.73615.d4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Plebani M, Banfi G, Bernardini S, Bondanini F, Conti L, Dorizzi R, Ferrara FE, Mancini R, Trenti T. Serum or plasma? An old question looking for new answers. Clin Chem Lab Med 2020;58:178-87. [PMID: 31525152 DOI: 10.1515/cclm-2019-0719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
2 Cavalcoli F, Rossi RE, Massironi S. Circulating Biochemical Markers of Gastro-Entero-Pancreatic (GEP) Neuroendocrine Neoplasms (NENs). Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_5] [Reference Citation Analysis]
3 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
4 Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, Appetecchia M. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers (Basel) 2019;11:E1113. [PMID: 31382663 DOI: 10.3390/cancers11081113] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
5 Dittadi R, Bertoli I. Evaluation of an ELISA Method for the Measurement of Chromogranin a and Comparison with an Immunoradiometric Method. Int J Biol Markers 2013;28:114-6. [DOI: 10.5301/jbm.2012.9586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Appetecchia M, Lauretta R, Rota F, Carlini M. Neuroendocrine Tumors Biomarkers. Updates in Surgery 2018. [DOI: 10.1007/978-88-470-3955-1_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocrine-Related Cancer 2018;25:R11-29. [DOI: 10.1530/erc-17-0269] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 15.6] [Reference Citation Analysis]
8 Koenig A, Krug S, Mueller D, Barth PJ, Koenig U, Scharf M, Ellenrieder V, Michl P, Moll R, Homayunfar K, Kann PH, Stroebel P, Gress TM, Rinke A. Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms. PLoS One 2017;12:e0188876. [PMID: 29232390 DOI: 10.1371/journal.pone.0188876] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
9 Nanno Y, Toyama H, Matsumoto I, Otani K, Asari S, Goto T, Ajiki T, Zen Y, Fukumoto T, Ku Y. Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: A potential predictor of postoperative recurrence. Pancreatology 2017;17:291-4. [PMID: 28043759 DOI: 10.1016/j.pan.2016.12.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
10 Kidd M, Bodei L, Modlin IM. Chromogranin A: any relevance in neuroendocrine tumors? Curr Opin Endocrinol Diabetes Obes 2016;23:28-37. [PMID: 26627724 DOI: 10.1097/MED.0000000000000215] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
11 Tian T, Gao J, Li N, Li Y, Lu M, Li Z, Lu Z, Li J, Shen L. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors. PLoS One 2016;11:e0154679. [PMID: 27159453 DOI: 10.1371/journal.pone.0154679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
12 Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955 [PMID: 25684964 DOI: 10.3748/wjg.v21.i6.1945] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
13 Modlin IM, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei L, Kidd M. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr Relat Cancer. 2014;21:615-628. [PMID: 25015994 DOI: 10.1530/erc-14-0190] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 9.6] [Reference Citation Analysis]
14 Vinik AI. Advances in Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors. Endocrine Practice 2014;20:1222-30. [DOI: 10.4158/ep14373.ra] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
15 Pedersen L, Nybo M. Preanalytical factors of importance for measurement of Chromogranin A. Clinica Chimica Acta 2014;436:41-4. [DOI: 10.1016/j.cca.2014.04.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
16 Nadler A, Cukier M, Milot L, Singh S, Law CH. Hepatic parenchymal preserving technique in the management of diffuse bilateral neuroendocrine tumour liver metastases: a feasible approach. Can J Surg 2014;57:E2-8. [PMID: 24666455 DOI: 10.1503/cjs.014112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Singh S, Law C. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Review of Gastroenterology & Hepatology 2014;6:313-34. [DOI: 10.1586/egh.12.15] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
18 Bech P, Martin N, Ramachandran R, Bloom S. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia. Ann Clin Biochem 2014;51:8-21. [DOI: 10.1177/0004563213489670] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
19 Díaz Pérez JÁ, Currás Freixes M. Chromogranin A and neuroendocrine tumors. Endocrinología y Nutrición (English Edition) 2013;60:386-395. [DOI: 10.1016/j.endoen.2012.10.007] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Tellez MR, Mamikunian G, O'Dorisio TM, Vinik AI, Woltering EA. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas 2013;42:405-10. [PMID: 23160483 DOI: 10.1097/MPA.0b013e318271c0d5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
21 Khan MS, Caplin ME. The use of biomarkers in neuroendocrine tumours. Frontline Gastroenterol 2013;4:175-81. [PMID: 28839724 DOI: 10.1136/flgastro-2012-100272] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
22 Jensen KH, Hilsted L, Jensen C, Mynster T, Rehfeld JF, Knigge U. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scand J Gastroenterol 2013;48:70-7. [PMID: 23094948 DOI: 10.3109/00365521.2012.733953] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
23 Díaz Pérez JÁ, Currás Freixes M. [Chromogranin A and neuroendocrine tumors]. Endocrinol Nutr 2013;60:386-95. [PMID: 23271036 DOI: 10.1016/j.endonu.2012.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
24 Mamikunian P, Ardill JE, O'Dorisio TM, Krutzik SR, Vinik AI, Go VL, Armstrong L, Mamikunian G, Woltering EA. Validation of neurokinin a assays in the United States and Europe. Pancreas 2011;40:1000-5. [PMID: 21926539 DOI: 10.1097/MPA.0b013e318232b6a2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
25 Fiebrich HB, de Jong JR, Kema IP, Koopmans KP, Sluiter W, Dierckx RA, Walenkamp AM, Links TP, Brouwers AH, de Vries EG. Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. Eur J Nucl Med Mol Imaging 2011;38:1854-61. [PMID: 21698413 DOI: 10.1007/s00259-011-1862-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
26 Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America 2011;40:111-34. [DOI: 10.1016/j.ecl.2010.12.001] [Cited by in Crossref: 102] [Cited by in F6Publishing: 119] [Article Influence: 8.5] [Reference Citation Analysis]
27 Joseph S, Wang Y, Boudreaux JP, Anthony LB, Campeau R, Raines D, O’dorisio T, Go VL, Vinik AI, Cundiff J, Woltering EA. Neuroendocrine Tumors: Current Recommendations for Diagnosis and Surgical Management. Endocrinology and Metabolism Clinics of North America 2011;40:205-31. [DOI: 10.1016/j.ecl.2010.08.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
28 O'Dorisio TM, Krutzik SR, Woltering EA, Lindholm E, Joseph S, Gandolfi AE, Wang YZ, Boudreaux JP, Vinik AI, Go VL, Howe JR, Halfdanarson T, O'Dorisio MS, Mamikunian G. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas 2010;39:611-6. [PMID: 20124939 DOI: 10.1097/MPA.0b013e3181c68d7a] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
29 Jeske W, Glinicki P, Kapuścińska R. Commentary to "chromogranin a: biological function and clinical utility in neuroendocrine tumor disease". Ann Surg Oncol 2011;18:293. [PMID: 20549561 DOI: 10.1245/s10434-010-1146-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
30 Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17:2427-2443. [PMID: 20217257 DOI: 10.1245/s10434-010-1006-3] [Cited by in Crossref: 254] [Cited by in F6Publishing: 274] [Article Influence: 19.5] [Reference Citation Analysis]
31 Agborsangaya C, Toriola AT, Grankvist K, Surcel HM, Holl K, Parkkila S, Tuohimaa P, Lukanova A, Lehtinen M. The effects of storage time and sampling season on the stability of serum 25-hydroxy vitamin D and androstenedione. Nutr Cancer 2010;62:51-7. [PMID: 20043259 DOI: 10.1080/01635580903191460] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 6.1] [Reference Citation Analysis]
32 Vinik AI, Silva MP, Woltering EA, Go VL, Warner R, Caplin M. Biochemical testing for neuroendocrine tumors. Pancreas 2009;38:876-89. [PMID: 19855234 DOI: 10.1097/MPA.0b013e3181bc0e77] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 6.5] [Reference Citation Analysis]
33 Vinik E, Carlton CA, Silva MP, Vinik AI. Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors. Pancreas 2009;38:e87-95. [PMID: 19276865 DOI: 10.1097/MPA.0b013e31819b6441] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
34 . Bibliography. Current world literature. Growth and development. Curr Opin Endocrinol Diabetes Obes 2008;15:79-101. [PMID: 18185067 DOI: 10.1097/MED.0b013e3282f4f084] [Reference Citation Analysis]